The Manufacturers Life Insurance Company Decreases Stock Position in Disc Medicine, Inc. $IRON

The Manufacturers Life Insurance Company cut its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 38.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 32,493 shares of the company’s stock after selling 20,017 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.09% of Disc Medicine worth $2,078,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Arizona State Retirement System raised its stake in shares of Disc Medicine by 2.2% in the fourth quarter. Arizona State Retirement System now owns 6,798 shares of the company’s stock valued at $540,000 after acquiring an additional 144 shares during the period. Police & Firemen s Retirement System of New Jersey boosted its stake in shares of Disc Medicine by 3.3% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company’s stock worth $533,000 after purchasing an additional 215 shares during the period. AlphaCentric Advisors LLC grew its holdings in Disc Medicine by 5.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 3,972 shares of the company’s stock valued at $254,000 after purchasing an additional 216 shares during the last quarter. Kennedy Capital Management LLC grew its holdings in Disc Medicine by 3.3% during the 4th quarter. Kennedy Capital Management LLC now owns 9,324 shares of the company’s stock valued at $740,000 after purchasing an additional 296 shares during the last quarter. Finally, Alliancebernstein L.P. grew its holdings in Disc Medicine by 1.7% during the 3rd quarter. Alliancebernstein L.P. now owns 24,540 shares of the company’s stock valued at $1,622,000 after purchasing an additional 400 shares during the last quarter. 83.70% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Disc Medicine news, insider Rahul Khara sold 7,500 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $70.22, for a total transaction of $526,650.00. Following the sale, the insider owned 52,173 shares of the company’s stock, valued at approximately $3,663,588.06. The trade was a 12.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO John D. Quisel sold 34,000 shares of Disc Medicine stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $70.21, for a total transaction of $2,387,140.00. Following the sale, the chief executive officer owned 226,064 shares of the company’s stock, valued at $15,871,953.44. The trade was a 13.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 110,712 shares of company stock worth $7,997,536 in the last ninety days. 3.76% of the stock is owned by insiders.

Key Stories Impacting Disc Medicine

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: HC Wainwright raised its price target for Disc Medicine to $120 from $118 and maintained a Buy rating. The new target is well above recent trading levels and may support upside expectations. Price target article
• Positive Sentiment: HC Wainwright modestly improved its estimates for several periods, including FY2026 EPS to a loss of $6.64 from $6.72, Q4 2026 to a loss of $1.74 from $1.75 and FY2028 to a loss of $4.62 from $4.64. The revisions indicate slightly better expected results, although the company remains unprofitable. Earnings estimates article
• Neutral Sentiment: The analyst also lowered its FY2027 EPS forecast to a loss of $6.47 from $6.13 and trimmed its Q3 2026 estimate slightly to a loss of $1.71 from $1.70. Overall, the changes are limited and do not alter HC Wainwright’s Buy rating or $120 target.
• Negative Sentiment: Rosen Law Firm announced an ongoing investigation into potential securities claims alleging that Disc Medicine may have issued materially misleading information to investors. The announcement does not establish wrongdoing, but it adds legal and reputational uncertainty and could pressure the stock if additional claims or disclosures emerge. Rosen Law Firm investigation article
• Negative Sentiment: Insider Rahul Khara sold 5,000 shares for approximately $400,000, reducing his holdings by 8.72%. He continues to own a substantial position, so the sale may reflect portfolio or personal financial considerations, but it can still weigh on investor confidence. Insider selling article

Disc Medicine Price Performance

Shares of IRON opened at $77.44 on Monday. The company has a 50 day moving average price of $73.59 and a 200-day moving average price of $69.78. Disc Medicine, Inc. has a fifty-two week low of $40.00 and a fifty-two week high of $99.50. The stock has a market capitalization of $2.96 billion, a PE ratio of -11.77 and a beta of 1.00. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.71) by $0.17. Equities analysts predict that Disc Medicine, Inc. will post -6.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on IRON shares. Wedbush reissued an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a research note on Wednesday, June 10th. Wall Street Zen raised Disc Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a report on Friday, July 17th. Morgan Stanley raised their price target on Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a research note on Monday, June 15th. Finally, HC Wainwright boosted their price objective on Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a report on Thursday. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $106.00.

Disc Medicine Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.